Human protein kinase H2LAU20

ABSTRACT

The H2LAU20 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing H2LAU20 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

FIELD OF THE INVENTION

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

BACKGROUND OF THE INVENTION

The drug discovery process is currently undergoing a fundamental revolution as it embraces `functional genomics`, that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on `positional cloning`. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

A number of polypeptide growth factors and hormones mediate their cellular effects through a signal transduction pathway. Transduction of signals from the cell surface receptors for these ligands to intracellular effectors frequently involves phosphorylation or dephosphorylation of specific protein substrates by regulatory protein serine/threonine kinases (PSTK) and phosphatases. Serine/threonine phosphorylation is a major mediator of signal transduction in multicellular organisms. Receptor-bound, membrane-bound and intracellular PSTKs regulate cell proliferation, cell differentiation and signalling processes in many cell types.

Aberrant protein serine/threonine kinase activity has been implicated or is suspected in a number of pathologies such as rheumatoid arthritis, psoriasis, septic shock, bone loss, many cancers and other proliferative diseases. Accordingly, serine/threonine kinases and the signal transduction pathways which they are part of are potential targets for drug design.

A subset of PSTKs are involved in regulation of cell cycling. These are the cyclin-dependent kinases or CDKs (Peter and Herskowitz, Cell 1994: 79, 181-184). CDKs are activated by binding to regulatory proteins called cyclins and control passage of the cell through specific cell cycle checkpoints. For example, CDK2 complexed with cyclin E allows cells to progress through the G1 to S phase transition. The complexes of CDKs and cyclins are subject to inhibition by low molecular weight proteins such as p16 (Serrano et al, Nature 1993: 366, 704), which binds to and inhibits CDK4. Deletions or mutations in p16 have been implicated in a variety of tumors (Kamb et al, Science 1994: 264, 436-440). Therefore, the proliferative state of cells and diseases associated with this state are dependent on the activity of CDKs and their associated regulatory molecules. In diseases such as cancer where inhibition of proliferation is desired, compounds that inhibit CDKs may be useful therapeutic agents. Conversely, activators of CDKs may be useful where enhancement of proliferation is needed, such as in the treatment of immunodeficiency.

Frequently, in diseases such as osteoporosis and osteoarthritis, patients have established lesions of bone or cartilage, respectively. Treatment of such lesions requires an agent that will stimulate new bone or cartilage formation to replace that lost to the disease; therefore, there is a need for drugs that increase the number of osteoblasts or chondrocytes, the cells responsible for bone or cartilage formation, respectively. Similarly, replacement of heart or skeletal muscle depleted by diseases such as myocardial infarction or HIV-associated cachexia requires drugs that stimulate proliferation of cardiac myocytes or skeletal myoblasts. The present invention describes a novel human clone, H2LAU20, which shares homology with predicted PSTK's from S. pombe, D. melanogaster, C. elegans, and S. cerevisiae and has motifs associated with other known protein kinases. Inhibitors of H2LAU20 are expected to regulate proliferation of cell growth.

SUMMARY OF THE INVENTION

The present invention relates to H2LAU20, in particular H2LAU20 polypeptides and H2LAU20 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; diabetes and associated disorders; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular diseases including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, hereinafter referred to as "the Diseases", amongst others In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with H2LAU20imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate H2LAU20 activity or levels.

DESCRIPTION OF THE INVENTION

In a first aspect, the present invention relates to H2LAU20polypeptides. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

Polypeptides of the present invention are believed to be members of the serine/threonine kinase family of polypeptides. They are therefore of interest because aberrant protein serine/threonine kinase activity has been implicated or is suspected in a number of pathologies such as rheumatoid arthritis, psoriasis, septic shock, bone loss, many cancers and other proliferative diseases. Accordingly, serine/threonine kinases and the signal transduction pathways which they are part of are potential targets for drug design. These properties are hereinafter referred to as "H2LAU20 activity" or "H2LAU20 polypeptide activity" or "biological activity of 12LAU20. Also included amongst these activities are antigenic and immunogenic activities of said H2LAU20 polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2. Preferably, a polypeptide of the present invention exhibits at least one biological activity of H2LAU20.

The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to H2LAU20 polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity,to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to SEQ ID NO:1 over the entire length of SEQ ID NO:1. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 as well as the polynucleotide of SEQ ID NO:1.

The invention also provides polynucleotides which are complementary to all the above-described polynucleotides.

The nucleotide sequence of SEQ ID NO:1 shows homology with Human protein kinase YAK1 (U.S. Ser. No. 08/802,466), and Human protein kinase YAK3 (U.S. Ser. No. 08/835,170). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1863) encoding a polypeptide of 620 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of SEQ ID NO:2 is structurally related to other proteins of the serine/threonine kinase family, having homology and/or structural similarity with C. elegans protein kinase F49E11.1 (Wilson et al., Nature 368: 32-38, 1994) and Human protein kinase YAK1 (U.S. Ser. Number 08/802,466).

Preferred polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one H1LAU20 activity.

The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1 and SEQ ID NO:2.

Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide comprising:

(a) a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

(b) a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

(c) the polynucleotide of SEQ ID NO:3; or

(d) a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4; as well as the polynucleotide of SEQ ID NO:3.

The present invention further provides for a polypeptide which:

(a) comprises an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

(b) has an amino acid sequence which is at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

(c) comprises the amino acid of SEQ ID NO:4; and

(d) is the polypeptide of SEQ ID NO:4; as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognized by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M. D. et al, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded therefrom are subject to the same inherent limitations in sequence accuracy. Furthermore, the peptide sequence encoded by SEQ ID NO:3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human placenta, using the expressed sequence tag (EST) analysis (Adams, M. D., el al. Science (1991) 252:1651-1656; Adams, M. D. et al., Nature, (1992) 355:632-634; Adams, M. D., et al., Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well-known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence, which facilitates purification of the fused polypeptide, can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to SEQ ID NO:1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42° C. in a solution comprising: 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 microgram/ml denatured, sheared salmon spenn DNA; followed by washing the filters in 0.1×SSC at about 65° C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stingent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is cut short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low `processivity` (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an `adaptor` sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the `missing` 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using `nested` primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to hostcells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al, Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C 127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host, may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (supra). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well-known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterized by the polynucleotide of SEQ ID NO:1 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled H2LAU20 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (ee, e.g., Myers et al., Science (1985) 230: 1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton et al., Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising H2LAU20 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M. Chee et al., Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the H2LAU20 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof, or

(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; diabetes and associated disorders; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, amongst others.

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique, which provides antibodies produced by continuous cell line cultures, can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256: 495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today (1983) 4: 72) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Pat. No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. W094/29458 and W094/22914.

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.

A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention. The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention are responsible for many biological functions, including many disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirous to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring H2LAU20activity in the mixture, and comparing the H2LAU20 activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and H2LAU20 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett et al., J Mol Recognition, 8: 52-58 (1995); and K. Johanson et al., J Biol Chem, 270(16):9459-9471(1995)).

The knowledge that the H2LAU20 encodes a putative protein kinase suggests that recombinant forms can be used to establish a protein kinase activity. Typically, this would involve the direct incubation of H2LAU20 with a protein or peptide substrate in the presence of 32P-ATP, followed by the measurement of radioactivity incorporated into the substrate by separation and counting. Separation methods include immunoprecipitation, conjugation of substrate to a bead allowing separation by centrifugation or determination of incorporation by scintillation proximity assay, SDS-PAGE followed by autoradiography or biosensor analysis. While the specific substrates are not yet known, candidates include H2LAU20 itself (autophosphorylation), myelin basic protein, casein, histone and HSP27. Other substances might be discovered by incubating H2LAU20 with random peptides conjugated to solid supports or displayed on the surface of phage or by incubation of H2LAU20 with mammalian cell lysates and 32P-ATP, followed by separation of the labelled target proteins, and sequencing. The protein kinase activity of H2LAU20 may require incubation with a specific upstream effector. This may be achieved by preincubating H2LAU20 with lysates from a variety of stimulated eukaryotic cells and ATP. These assays permit the discovery and modification of compounds which inhibit H2LAU20 kinase activity in vitro and would be expected to have effects on proliferation of osteoblasts, chondrocytes, cardiac myocytes or skeletal myoblasts. Any inhibitors so identified would be expected to have up-regulatory effects on proliferation and be useful as a therapeutic for the treatment and prevention of diseases such as osteoporosis, osteoarthritis, cardiomyopathy and cachexia.

This invention is also directed to the treatment and/or amelioration of such diseases by administering an H2LAU20 inhibiting amount of a compound. Without wishing to be bound by any particular theory of the functioning of the H2LAU20 of this invention, among the useful inhibitors of H2LAU20 function are those compounds which inhibit the kinase activity of the H2LAU20. Other sites of inhibition are, of course, possibly owing to its position in a signal transduction cascade. Therefore, the present invention is also directed to inhibiting the interaction of H2LAU20 with one or more of its upstream or downstream modulators/substrates. Inhibitors of protein-protein interactions between H2LAU20 and other factors could lead to the development of pharmaceutical agents for the modulation of H2LAU20 activity.

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide(also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ¹²⁵ I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

(a) a polypeptide of the present invention;

(b) a recombinant cell expressing a polypeptide of the present invention;

(c) a cell membrane expressing a polypeptide of the present invention; or

(d) antibody to a polypeptide of the present invention; which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:

(a) determining in the first instance the three-dimensional structure of the polypeptide;

(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;

(c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

(d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors. It will be further appreciated that this will normally be an interactive process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; diabetes and associated disorders; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, related to either an excess of, or an under-expression of, H2LAU20 polypeptide activity.

If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the H2LAU20 polypeptide.

In still another approach, expression of the gene encoding endogenous H2LAU20 polypeptide can be inhibited using expression-blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, J Neurochem (1991) 56: 560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Alternatively, oligonucleotides which form triple helices with the gene can be supplied (see, for example, Lee et al., Nucleic Acids Res (1979) 6: 3073; Cooney et al., Science (1988) 241: 456; Dervan et al., Science (1991) 251: 1360). These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.

For treating abnormal conditions related to an under-expression of H2LAU20 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of H2LAU20 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 μg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as GCC. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 and/or a polypeptide sequence encoded thereby.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of a Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well-described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al., "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol (1990) 182: 626-646 and Rattan et al., "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci (1992) 663: 48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, and deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J Applied Math., 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to deterinine identity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1). 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., J. Molec. Biol. 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (Blast manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al, J. Mol. Biol. 215: 403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA.

89: 10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison Wis. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Parameters for polynucleotide comparison include the following:

1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches=+10, mismatch=0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison Wis. These are the default parameters for nucleic acid comparisons.

A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

    n.sub.n ≦x.sub.n -(x.sub.n ·y)

wherein n_(n) is the number of nucleotide alterations, x_(n) is the total number of nucleotides in SEQ ID NO:1, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and · is the symbol for the multiplication operator, and wherein any non-integer product of x_(n), and y is rounded down to the nearest integer prior to subtracting it from x_(n). Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

    n.sub.n ≦x.sub.n -(x.sub.n ·y),

wherein n_(n) is the number of amino acid alterations, x_(n) is the total number of amino acids in SEQ ID NO:2, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., · is the symbol for the multiplication operator, and wherein any non-integer product of x_(n) and y is rounded down to the nearest integer prior to subtracting it from x_(n).

(2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ID NO:2 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

    n.sub.a ≦x.sub.a -(x.sub.a ·y),

wherein n_(a) is the number of amino acid alterations, x_(a) is the total number of amino acids in SEQ ID NO:2, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and · is the symbol for the multiplication operator, and wherein any non-integer product of x_(a) and y is rounded down to the nearest integer prior to subtracting it from x_(a).

By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

    n.sub.a ≦x.sub.a -(x.sub.a ·y),

wherein n_(a) is the number of amino acid alterations, x_(a) is the total number of amino acids in SEQ ID NO:2, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and · is the symbol for the multiplication operator, and wherein any non-integer product of x_(a) and y is rounded down to the nearest integer prior to subtracting it from x_(a).

"Fusion protein" refers to a protein encoded by two, often unrelated, and fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

    __________________________________________________________________________     SEQUENCE INFORMATION                                                           __________________________________________________________________________     SEQ ID NO:1                                                                      - ATGGATGCTAAAAAGCCAAGGAAATGTGATTTGACTCCCTTCCTGGTTTTGAAAGCAAGA                 - AAGAAACAAAAGTTCACCTCTGCGAAGGTTGGAAGTAAACTTTCGGTTCAGATCCAGAAG                 - CCACCTTCCAATATCAAGAACTCCAGAATGACCCAAGTCTTTCATAAGAACACCAGTGTT                 - ACTTCACTCCCCTTTGTGGACACCAAGGGGAAGAAGAATACGGTAAGCTTCCCACACATT                 - AGCAAGAAAGTCCTGCTGAAGTCATCCCTGCTGTATCAGGAGAATCAAGCTCACAATCAG                 - ATGCCGGCCTCAGAGCTCAAGGCTTCAGAAATACCTTTCCACCCTAGCATTAAAACCCAG                 - GATCCCAAGGCAGAGGAGAAGTCACCAAAGAAGCAAAAGGTGACTCTGACAGCGGCAGAG                 - GCCCTAAAGCTTTTTAAGAACCAGCTGTCTCCATATGAACAAAGTGAAATCCTGGGCTAC                 - GCGGAGCTGTGGTTCCTGGGTCTTGAAGCCAAGAAGCTCGACACGGCTCCTGAGAAATTT                 - AGCAAGACGAGTTTTGATGATGAGCATGGCTTCTATCTGAAGGTCCTGCATGATCACATT                 - GCCTACCGCTATGAAGTTCTGGAGACAATCGGGAAGGGGTCCTTTGGACAGGTGGCCAAG                 - TGCTTGGATCACAAAAACAATGAGCTGGTGGCCCTGAAAATCATCAGGAACAAGAAGAGG                 - TTTCACCAGCAGGCCCTGATGGAGCTGAAGATCCTGGAAGCTCTCAGAAAGAAGGACAAA                 - GACAACACCTACAATGTGGTGCATATGAAGGACTTTTTCTACTTTCGCAATCACTTCTGC                 - ATCACCTTTGAGCTCCTGGGAATCAACTTGTATGAGTTGATGAAGAATAACAACTTTCAA                 - GGCTTCAGTCTGTCCATAGTTCGGCGCTTCACTCTCTCTGTTTTGAAGTGCTTGCAGATG                 - CTTTCGGTAGAGAAAATCATTCACTGTGATCTCAAGCCCGAAAATATAGTGCTATACCAA                 - AAGGGCCAAGCCTCTGTTAAAGTCATTGACTTTGGATCAAGCTGTTATGAACACCAGAAA                 - GTATACACGTACATCCAAAGCCGGTTCTACCGATCCCCAGAAGTGATCCTGGGCCACCCC                 - TACGACGTGGCCATTGACATGTGGAGCCTGGGCTGCATCACGGCGGAGTTGTACACGGGC                 - TACCCCCTGTTCCCCGGGGAGAATGAGGTGGAGCAGCTGGCCTGCATCATGGAGGTGCTG                 - GGTCTGCCGCCAGCCGGCTTCATTCAGACAGCCTCCAGGAGACAGACATTCTTTGATTCC                 - AAAGGTTTTCCTAAAAATATAACCAACAACAGGGGGAAAAAAAGATACCCAGATTCCAAG                 - GACCTCACGATGGTGCTGAAAACCTATGACACCAGCTTCCTGGACTTTCTCAGAAGGTGT                 - TTGGTATGGGAACCTTCTCTTCGCATGACCCCGGACCAGGCCCTCAAGCATGCTTGGATT                 - TTGGTATGGGAACCTTCTCTTCGCATGACCCCGGACCAGGCCCTCAAGCATGCTTGGATT                 - CATCAGTCTCGGAACCTCAAGCCACAGCCCAGGCCCCAGACCCTGAGGAAATCCAATTCC                 - TTTTTCCCCTCTGAGACAAGGAAGGACAAGGTTCAAGGCTGTCATCACTCGAGCAGAAAA                 - GCAGATGAGATCACCAAAGAGACTACAGAGAAAACAAAAGATAGCCCCACGAAGCATGTT                 - CAGCATTCAGGTGATCAGCAGGACTGTCTCCAGCACGGAGCTGACACTGTTCAGCTGCCT                 - CAACTGGTAGACGCTCCCAAGAAGTCAGAGGCAGCTGTCGGGGCGGAGGTGTCCATGACC                 - TCCCCAGGACAGAGCAAAAACTTCTCCCTCAAGAACACAAACGTTTTACCCCCTATTGTA                 - TGA                                                                          - SEQ ID NO:2                                                                  - MDAKKPRKCDLTPFLVLKARKKQKFTSAKVGSKLSVQIQKPPSNIKNSRMTQVFHKNTSV                 - TSLPFVDTKGKKNTVSFPHISKKVLLKSSLLYQENQAHNQMPASELKASEIPFHPSIKTQ                 - DPKAEEKSPKKQKVTLTAAEALKLFKNQLSPYEQSEILGYAELWFLGLEAKKLKTAPEKF                 - SKTSFDDEHGFYLKVLHDHIAYRYEVLETIGKGSFGQVAKCLDHKNNELVALKIIRNKKR                 - FHQQALMELKILEALRKKDKDNTYNVVHMKDFFYFRNHFCITFELLGINLYELMKNNNFQ                 - GFSLSIVRRFTLSVLKCLQMLSVEKIIHCDLKPENIVLYQKGQASVKVIDFGSSCYEHQK                 - VYTYIQSRFYRSPEVILGHPYDVAIDMWSLGCITAELYTGYPLFPGENEVEQLACIMEVL                 - GLPPAGEFIQTASRRQTFFDSKGFPKNITNNRGKKRYPDSKDLTMVKTYDTSFLDFLRRC                 - LVWEPSLRMTPDQALKHAWIHQSRNLKPQPRPQTLRKSNSFFPSETRKDKVQGCHHSSRK                 - ADEITKETTEKTKDSPTKHVQHSGDQQDCLQHGADTVQLPQLVDAPKKSEAAVGAEVSMT                 - SPGQSKNFSLKNTNVLPPIV*                                                        - SEQ ID NO:3                                                                  -   1 GGCACGAGGT GGCCATTGAC ATGTGGAGCC TGGGCTGCAT CACGGCGGAG                   -  51 TTGTACACGG GCTACCCCCT GTTCCCCGGG GAGAATGAGG TGGAGCAGCT                   - 101 GGCCTGCATC ATGGAGGTGC TGGGTCTGCC GCCAGCCGGC TTCATTCAGA                   - 151 CAGCCTCCAG GAGACAGACA TTCTTTGATT CCAAAGGTTT TCCTAAAAAT                   - 201 ATAACCAACA ACAGGGGGAA AAAAAGATAC CCAGATTCCA AGGACCTCAC                   - 251 GATGGTGCTG AAAACCTATG ACACCAGCTT CCTGGACTTT CTCAGAAGGT                   - 301 GTTTGGTATG GGAACCTTCT CTTCGCATGA CCCCGGACCA GGCCCTCAAG                   - 351 CATGCTTGGA TTCATCAGTC TcGGAACCTC AAGCCACAGC CCAGGCCCCA                   - 401 GACCCTGAGG AAATCCAATT CCTTTTTCCC CTCTGAGACA AGGAAgGACA                   - 451 AGGTTCAAGG CTGTCATCaC TCGAGCAGAA AAGATGAGAT CACCAAAGAG                   - 501 ACTACAGAGA AAACAAAAGA TAGCCCCACG AAGCATGTTC AGCATTCAGG                   - 551 TGATCAGCAG GACTGTCTCC AGCACGGAGC TGACACTGTT CAGCTGCCTC                   - 601 AACTGGTAGA CGCTCCCAAG AAGTCAGAGG CAGCTGTCGG GGCGGAGGTG                   - 651 TCCATGACCT CCCCAGGACA GAGCAAAAAC TTCTCCCTCA AGAACACAAA                   - 701 CGTTTTACCC CCTATTGTAT GACCTTTGCT GAGGGTATGT CCTGCTCCTT                   - 751 TCCACCAGTG ATTTGTATTA AGACAGCACT TATATTGTAC AATACTTCAG                   - 801 ACTGTTTTTT TTAAATACAT AAAACTTTAT GTTAAAAAAA AAAAAAAAAA                   - 851 A                                                                        - SEQ ID NO:4                                                                  -   1 HEVAIDMWSL GCITAELYTG YPLFPGENEV EQLACIMEVL GLPPAGFIQT                   -  51 ASRRQTFFDS KGFPKNITNN RGKKRYPDSK DLTMVLKTYD TSFLDFLRRC                   - 101 LVWEPSLRMT PDQALKHAWI HQSRNLKPQP RPQTLRKSNS FFPSETRKDK                   - 151 VQGCHHSSRK DEITKETTEK TKDSPTKHVQ HSGDQQDCLQ HGADTVQLPQ                   - 201 LVDAPKKSEA AVGAEVSMTS PGQSKNFSLK NTNVLPPIV                             __________________________________________________________________________

    __________________________________________________________________________     #             SEQUENCE LISTING                                                   - -  - - (1) GENERAL INFORMATION:                                              - -    (iii) NUMBER OF SEQUENCES: 4                                            - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1863 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: cDNA                                               - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                - - ATGGATGCTA AAAAGCCAAG GAAATGTGAT TTGACTCCCT TCCTGGTTTT GA -              #AAGCAAGA     60                                                                  - - AAGAAACAAA AGTTCACCTC TGCGAAGGTT GGAAGTAAAC TTTCGGTTCA GA -             #TCCAGAAG    120                                                                  - - CCACCTTCCA ATATCAAGAA CTCCAGAATG ACCCAAGTCT TTCATAAGAA CA -             #CCAGTGTT    180                                                                  - - ACTTCACTCC CCTTTGTGGA CACCAAGGGG AAGAAGAATA CGGTAAGCTT CC -             #CACACATT    240                                                                  - - AGCAAGAAAG TCCTGCTGAA GTCATCCCTG CTGTATCAGG AGAATCAAGC TC -             #ACAATCAG    300                                                                  - - ATGCCGGCCT CAGAGCTCAA GGCTTCAGAA ATACCTTTCC ACCCTAGCAT TA -             #AAACCCAG    360                                                                  - - GATCCCAAGG CAGAGGAGAA GTCACCAAAG AAGCAAAAGG TGACTCTGAC AG -             #CGGCAGAG    420                                                                  - - GCCCTAAAGC TTTTTAAGAA CCAGCTGTCT CCATATGAAC AAAGTGAAAT CC -             #TGGGCTAC    480                                                                  - - GCGGAGCTGT GGTTCCTGGG TCTTGAAGCC AAGAAGCTCG ACACGGCTCC TG -             #AGAAATTT    540                                                                  - - AGCAAGACGA GTTTTGATGA TGAGCATGGC TTCTATCTGA AGGTCCTGCA TG -             #ATCACATT    600                                                                  - - GCCTACCGCT ATGAAGTTCT GGAGACAATC GGGAAGGGGT CCTTTGGACA GG -             #TGGCCAAG    660                                                                  - - TGCTTGGATC ACAAAAACAA TGAGCTGGTG GCCCTGAAAA TCATCAGGAA CA -             #AGAAGAGG    720                                                                  - - TTTCACCAGC AGGCCCTGAT GGAGCTGAAG ATCCTGGAAG CTCTCAGAAA GA -             #AGGACAAA    780                                                                  - - GACAACACCT ACAATGTGGT GCATATGAAG GACTTTTTCT ACTTTCGCAA TC -             #ACTTCTGC    840                                                                  - - ATCACCTTTG AGCTCCTGGG AATCAACTTG TATGAGTTGA TGAAGAATAA CA -             #ACTTTCAA    900                                                                  - - GGCTTCAGTC TGTCCATAGT TCGGCGCTTC ACTCTCTCTG TTTTGAAGTG CT -             #TGCAGATG    960                                                                  - - CTTTCGGTAG AGAAAATCAT TCACTGTGAT CTCAAGCCCG AAAATATAGT GC -             #TATACCAA   1020                                                                  - - AAGGGCCAAG CCTCTGTTAA AGTCATTGAC TTTGGATCAA GCTGTTATGA AC -             #ACCAGAAA   1080                                                                  - - GTATACACGT ACATCCAAAG CCGGTTCTAC CGATCCCCAG AAGTGATCCT GG -             #GCCACCCC   1140                                                                  - - TACGACGTGG CCATTGACAT GTGGAGCCTG GGCTGCATCA CGGCGGAGTT GT -             #ACACGGGC   1200                                                                  - - TACCCCCTGT TCCCCGGGGA GAATGAGGTG GAGCAGCTGG CCTGCATCAT GG -             #AGGTGCTG   1260                                                                  - - GGTCTGCCGC CAGCCGGCTT CATTCAGACA GCCTCCAGGA GACAGACATT CT -             #TTGATTCC   1320                                                                  - - AAAGGTTTTC CTAAAAATAT AACCAACAAC AGGGGGAAAA AAAGATACCC AG -             #ATTCCAAG   1380                                                                  - - GACCTCACGA TGGTGCTGAA AACCTATGAC ACCAGCTTCC TGGACTTTCT CA -             #GAAGGTGT   1440                                                                  - - TTGGTATGGG AACCTTCTCT TCGCATGACC CCGGACCAGG CCCTCAAGCA TG -             #CTTGGATT   1500                                                                  - - CATCAGTCTC GGAACCTCAA GCCACAGCCC AGGCCCCAGA CCCTGAGGAA AT -             #CCAATTCC   1560                                                                  - - TTTTTCCCCT CTGAGACAAG GAAGGACAAG GTTCAAGGCT GTCATCACTC GA -             #GCAGAAAA   1620                                                                  - - GCAGATGAGA TCACCAAAGA GACTACAGAG AAAACAAAAG ATAGCCCCAC GA -             #AGCATGTT   1680                                                                  - - CAGCATTCAG GTGATCAGCA GGACTGTCTC CAGCACGGAG CTGACACTGT TC -             #AGCTGCCT   1740                                                                  - - CAACTGGTAG ACGCTCCCAA GAAGTCAGAG GCAGCTGTCG GGGCGGAGGT GT -             #CCATGACC   1800                                                                  - - TCCCCAGGAC AGAGCAAAAA CTTCTCCCTC AAGAACACAA ACGTTTTACC CC -             #CTATTGTA   1860                                                                  - - TGA                  - #                  - #                  - #                1863                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 620 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                - - Met Asp Ala Lys Lys Pro Arg Lys Cys Asp Le - #u Thr Pro Phe Leu Val        1               5  - #                10  - #                15                - - Leu Lys Ala Arg Lys Lys Gln Lys Phe Thr Se - #r Ala Lys Val Gly Ser                   20      - #            25      - #            30                    - - Lys Leu Ser Val Gln Ile Gln Lys Pro Pro Se - #r Asn Ile Lys Asn Ser               35          - #        40          - #        45                        - - Arg Met Thr Gln Val Phe His Lys Asn Thr Se - #r Val Thr Ser Leu Pro           50              - #    55              - #    60                            - - Phe Val Asp Thr Lys Gly Lys Lys Asn Thr Va - #l Ser Phe Pro His Ile       65                  - #70                  - #75                  - #80         - - Ser Lys Lys Val Leu Leu Lys Ser Ser Leu Le - #u Tyr Gln Glu Asn Gln                       85  - #                90  - #                95                - - Ala His Asn Gln Met Pro Ala Ser Glu Leu Ly - #s Ala Ser Glu Ile Pro                   100      - #           105      - #           110                   - - Phe His Pro Ser Ile Lys Thr Gln Asp Pro Ly - #s Ala Glu Glu Lys Ser               115          - #       120          - #       125                       - - Pro Lys Lys Gln Lys Val Thr Leu Thr Ala Al - #a Glu Ala Leu Lys Leu           130              - #   135              - #   140                           - - Phe Lys Asn Gln Leu Ser Pro Tyr Glu Gln Se - #r Glu Ile Leu Gly Tyr       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Ala Glu Leu Trp Phe Leu Gly Leu Glu Ala Ly - #s Lys Leu Asp Thr         Ala                                                                                              165  - #               170  - #               175              - - Pro Glu Lys Phe Ser Lys Thr Ser Phe Asp As - #p Glu His Gly Phe Tyr                   180      - #           185      - #           190                   - - Leu Lys Val Leu His Asp His Ile Ala Tyr Ar - #g Tyr Glu Val Leu Glu               195          - #       200          - #       205                       - - Thr Ile Gly Lys Gly Ser Phe Gly Gln Val Al - #a Lys Cys Leu Asp His           210              - #   215              - #   220                           - - Lys Asn Asn Glu Leu Val Ala Leu Lys Ile Il - #e Arg Asn Lys Lys Arg       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe His Gln Gln Ala Leu Met Glu Leu Lys Il - #e Leu Glu Ala Leu         Arg                                                                                              245  - #               250  - #               255              - - Lys Lys Asp Lys Asp Asn Thr Tyr Asn Val Va - #l His Met Lys Asp Phe                   260      - #           265      - #           270                   - - Phe Tyr Phe Arg Asn His Phe Cys Ile Thr Ph - #e Glu Leu Leu Gly Ile               275          - #       280          - #       285                       - - Asn Leu Tyr Glu Leu Met Lys Asn Asn Asn Ph - #e Gln Gly Phe Ser Leu           290              - #   295              - #   300                           - - Ser Ile Val Arg Arg Phe Thr Leu Ser Val Le - #u Lys Cys Leu Gln Met       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Leu Ser Val Glu Lys Ile Ile His Cys Asp Le - #u Lys Pro Glu Asn         Ile                                                                                              325  - #               330  - #               335              - - Val Leu Tyr Gln Lys Gly Gln Ala Ser Val Ly - #s Val Ile Asp Phe Gly                   340      - #           345      - #           350                   - - Ser Ser Cys Tyr Glu His Gln Lys Val Tyr Th - #r Tyr Ile Gln Ser Arg               355          - #       360          - #       365                       - - Phe Tyr Arg Ser Pro Glu Val Ile Leu Gly Hi - #s Pro Tyr Asp Val Ala           370              - #   375              - #   380                           - - Ile Asp Met Trp Ser Leu Gly Cys Ile Thr Al - #a Glu Leu Tyr Thr Gly       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Tyr Pro Leu Phe Pro Gly Glu Asn Glu Val Gl - #u Gln Leu Ala Cys         Ile                                                                                              405  - #               410  - #               415              - - Met Glu Val Leu Gly Leu Pro Pro Ala Gly Ph - #e Ile Gln Thr Ala Ser                   420      - #           425      - #           430                   - - Arg Arg Gln Thr Phe Phe Asp Ser Lys Gly Ph - #e Pro Lys Asn Ile Thr               435          - #       440          - #       445                       - - Asn Asn Arg Gly Lys Lys Arg Tyr Pro Asp Se - #r Lys Asp Leu Thr Met           450              - #   455              - #   460                           - - Val Leu Lys Thr Tyr Asp Thr Ser Phe Leu As - #p Phe Leu Arg Arg Cys       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Leu Val Trp Glu Pro Ser Leu Arg Met Thr Pr - #o Asp Gln Ala Leu         Lys                                                                                              485  - #               490  - #               495              - - His Ala Trp Ile His Gln Ser Arg Asn Leu Ly - #s Pro Gln Pro Arg Pro                   500      - #           505      - #           510                   - - Gln Thr Leu Arg Lys Ser Asn Ser Phe Phe Pr - #o Ser Glu Thr Arg Lys               515          - #       520          - #       525                       - - Asp Lys Val Gln Gly Cys His His Ser Ser Ar - #g Lys Ala Asp Glu Ile           530              - #   535              - #   540                           - - Thr Lys Glu Thr Thr Glu Lys Thr Lys Asp Se - #r Pro Thr Lys His Val       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Gln His Ser Gly Asp Gln Gln Asp Cys Leu Gl - #n His Gly Ala Asp         Thr                                                                                              565  - #               570  - #               575              - - Val Gln Leu Pro Gln Leu Val Asp Ala Pro Ly - #s Lys Ser Glu Ala Ala                   580      - #           585      - #           590                   - - Val Gly Ala Glu Val Ser Met Thr Ser Pro Gl - #y Gln Ser Lys Asn Phe               595          - #       600          - #       605                       - - Ser Leu Lys Asn Thr Asn Val Leu Pro Pro Il - #e Val                           610              - #   615              - #   620                           - -  - - (2) INFORMATION FOR SEQ ID NO:3:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 851 base - #pairs                                                  (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: cDNA                                               - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                - - GGCACGAGGT GGCCATTGAC ATGTGGAGCC TGGGCTGCAT CACGGCGGAG TT -              #GTACACGG     60                                                                  - - GCTACCCCCT GTTCCCCGGG GAGAATGAGG TGGAGCAGCT GGCCTGCATC AT -             #GGAGGTGC    120                                                                  - - TGGGTCTGCC GCCAGCCGGC TTCATTCAGA CAGCCTCCAG GAGACAGACA TT -             #CTTTGATT    180                                                                  - - CCAAAGGTTT TCCTAAAAAT ATAACCAACA ACAGGGGGAA AAAAAGATAC CC -             #AGATTCCA    240                                                                  - - AGGACCTCAC GATGGTGCTG AAAACCTATG ACACCAGCTT CCTGGACTTT CT -             #CAGAAGGT    300                                                                  - - GTTTGGTATG GGAACCTTCT CTTCGCATGA CCCCGGACCA GGCCCTCAAG CA -             #TGCTTGGA    360                                                                  - - TTCATCAGTC TCGGAACCTC AAGCCACAGC CCAGGCCCCA GACCCTGAGG AA -             #ATCCAATT    420                                                                  - - CCTTTTTCCC CTCTGAGACA AGGAAGGACA AGGTTCAAGG CTGTCATCAC TC -             #GAGCAGAA    480                                                                  - - AAGATGAGAT CACCAAAGAG ACTACAGAGA AAACAAAAGA TAGCCCCACG AA -             #GCATGTTC    540                                                                  - - AGCATTCAGG TGATCAGCAG GACTGTCTCC AGCACGGAGC TGACACTGTT CA -             #GCTGCCTC    600                                                                  - - AACTGGTAGA CGCTCCCAAG AAGTCAGAGG CAGCTGTCGG GGCGGAGGTG TC -             #CATGACCT    660                                                                  - - CCCCAGGACA GAGCAAAAAC TTCTCCCTCA AGAACACAAA CGTTTTACCC CC -             #TATTGTAT    720                                                                  - - GACCTTTGCT GAGGGTATGT CCTGCTCCTT TCCACCAGTG ATTTGTATTA AG -             #ACAGCACT    780                                                                  - - TATATTGTAC AATACTTCAG ACTGTTTTTT TTAAATACAT AAAACTTTAT GT -             #TAAAAAAA    840                                                                  - - AAAAAAAAAA A               - #                  - #                       - #      851                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:4:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 239 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: protein                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                - - His Glu Val Ala Ile Asp Met Trp Ser Leu Gl - #y Cys Ile Thr Ala Glu        1               5  - #                10  - #                15                - - Leu Tyr Thr Gly Tyr Pro Leu Phe Pro Gly Gl - #u Asn Glu Val Glu Gln                   20      - #            25      - #            30                    - - Leu Ala Cys Ile Met Glu Val Leu Gly Leu Pr - #o Pro Ala Gly Phe Ile               35          - #        40          - #        45                        - - Gln Thr Ala Ser Arg Arg Gln Thr Phe Phe As - #p Ser Lys Gly Phe Pro           50              - #    55              - #    60                            - - Lys Asn Ile Thr Asn Asn Arg Gly Lys Lys Ar - #g Tyr Pro Asp Ser Lys       65                  - #70                  - #75                  - #80         - - Asp Leu Thr Met Val Leu Lys Thr Tyr Asp Th - #r Ser Phe Leu Asp Phe                       85  - #                90  - #                95                - - Leu Arg Arg Cys Leu Val Trp Glu Pro Ser Le - #u Arg Met Thr Pro Asp                   100      - #           105      - #           110                   - - Gln Ala Leu Lys His Ala Trp Ile His Gln Se - #r Arg Asn Leu Lys Pro               115          - #       120          - #       125                       - - Gln Pro Arg Pro Gln Thr Leu Arg Lys Ser As - #n Ser Phe Phe Pro Ser           130              - #   135              - #   140                           - - Glu Thr Arg Lys Asp Lys Val Gln Gly Cys Hi - #s His Ser Ser Arg Lys       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Asp Glu Ile Thr Lys Glu Thr Thr Glu Lys Th - #r Lys Asp Ser Pro         Thr                                                                                              165  - #               170  - #               175              - - Lys His Val Gln His Ser Gly Asp Gln Gln As - #p Cys Leu Gln His Gly                   180      - #           185      - #           190                   - - Ala Asp Thr Val Gln Leu Pro Gln Leu Val As - #p Ala Pro Lys Lys Ser               195          - #       200          - #       205                       - - Glu Ala Ala Val Gly Ala Glu Val Ser Met Th - #r Ser Pro Gly Gln Ser           210              - #   215              - #   220                           - - Lys Asn Phe Ser Leu Lys Asn Thr Asn Val Le - #u Pro Pro Ile Val           225                 2 - #30                 2 - #35                           __________________________________________________________________________ 

What is claimed is:
 1. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 95% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2, said identity being calculated by n_(a) ≦x_(a) -(x_(a) ·y), wherein n_(a) is the number of amino acid alterations, x_(a) is the total number of amino acids in SEQ ID NO:2, and y is 0.95.
 2. An expression system comprising a polynucleotide capable of producing a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2 when said expression system is present in a compatible host cell.
 3. A process for producing a recombinant host cell comprising transforming or transfecting a cell with an isolated polynucleotide of claim
 1. 4. A recombinant host cell produced by the process of claim
 3. 5. A process for producing a polypeptide comprising culturing a host cell of claim 4 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
 6. An isolated polynucleotide comprising the polynucleotide sequence set forth in SEQ ID NO:3.
 7. An isolated polynucleotide comprising a nucleotide sequence which has at least 95% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO:1, said identity being calculated by n_(n) ≦x_(n) -(x_(n) ·y), wherein n_(n) is the number of nucleotide alterations, x_(n) is the total number of nucleotides in the nucleotide sequence encoding for SEQ ID NO:2, and y is 0.95.
 8. An isolated polynucleotide according to claim 1, wherein said isolated polynucleotide comprises a nucleotide sequence encoding the polypeptide of SEQ ID NO:2.
 9. An isolated polynucleotide according to claim 7 wherein said polynucleotide comprises the polynucleotide sequence set forth in SEQ ID NO:
 1. 10. An isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1, said stringent conditions comprising 50% formamide, 5×SSC, 50 mM sodium phosphate having pH7.6, 5×Denhardt's solution, 10% dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1×SSC at 65° C.
 11. A polynucleotide sequence which is fully complementary to any of the isolated polynucleotides in any one of claims 1, 7, 9, or 10, said identity being over the entire length of said isolated polynucleotide.
 12. An isolated polynucleotide according to claim 6 wherein said polynucleotide consists of the polynucleotide sequence set forth in SEQ ID NO:3. 